Discovery of novel adenylyl cyclase inhibitor by cell-based screening

Biol Pharm Bull. 2014;37(10):1689-93. doi: 10.1248/bpb.b14-00283.

Abstract

We screened 2400 compounds to find novel inhibitors of the adenylyl cyclase (AC)-protein kinase A (PKA)-cAMP response-element-binding protein (CREB) signaling pathway (AC/PKA/CREB pathway). Using a multistep cell-based screening system employing split luciferase technique, we narrowed down the candidates effectively from 2400 chemical compounds and identified a novel AC inhibitor (compound 1). Since dysregulation of the AC/PKA/CREB pathway is known to cause diseases not only in the nervous system but also in other organs, compound 1 is expected to be developed as a medicine for these diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylyl Cyclase Inhibitors*
  • Adenylyl Cyclases / metabolism
  • Dose-Response Relationship, Drug
  • Drug Discovery / methods*
  • Drug Evaluation, Preclinical / methods
  • Enzyme Inhibitors / chemistry*
  • Enzyme Inhibitors / pharmacology*
  • HEK293 Cells
  • Humans

Substances

  • Adenylyl Cyclase Inhibitors
  • Enzyme Inhibitors
  • Adenylyl Cyclases